[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-364462-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-364462-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","development-of-animal-models-to-study-aggressive-thyroid-cancers","Development of animal models to study aggressive thyroid cancers","","Mouse models of thyroid cancer have progressed substantially, improving understanding of thyroid tumorigenesis, molecular signaling, and therapy responses. Early models induced tumors through hormones, radiation, or chemical carcinogens, but they lacked specificity for the human genetic alterations driving the disease. As genomic knowledge expanded, thyroid-targeted genetic engineering enabled models carrying driver mutations expressed in thyroid tissue. Driver alterations alone often fail to sustain progression and invasion, prompting development of models that incorporate cooperating secondary mutations identified in advanced cancers. These combinations better recapitulate advanced thyroid cancer biology and support preclinical studies of how cooperating changes modify treatment response, especially to therapies targeting oncogenic drivers. This review emphasizes recent efforts integrating thyroid-specific driver expression with cooperating mutations.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/development-of-animal-models-to-study-aggressive-thyroid-cancers/364462/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/development-of-animal-models-to-study-aggressive-thyroid-cancers/364462.png","ImageObject",300,407,{"name":42,"@type":43},"Hazel","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-12","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",11,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"How did early mouse models of thyroid cancer induce tumors, and what were their limitations?","Question",{"text":63,"@type":64},"Early models used hormones, radiation, or chemical carcinogens to induce thyroid tumors. They showed high variability, long latency, poor penetrance, and limited relevance to the genetic basis of human thyroid cancer.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Why are driver mutations alone often insufficient for advanced thyroid cancer research?",{"text":68,"@type":64},"Although driver mutations can initiate tumorigenesis, they are frequently insufficient to sustain progression and invasion, limiting their ability to model advanced thyroid cancers.",{"name":70,"@type":61,"acceptedAnswer":71},"What is the purpose of combining oncogenic drivers with cooperating mutations in mouse models?",{"text":72,"@type":64},"Combining drivers with cooperating alterations creates models that more accurately promote progression to advanced thyroid cancer and helps evaluate how these cooperating changes influence responses to therapies targeting oncogenic drivers.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},364462,1790784618,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":33,"preview_urls":147},137441390410,"https://ap-avatar.wpscdn.com/avatar/2000252f4ab5702993?_k=1776741390130283984","European Thyroid Journal (2025) 14 e240361  \n[https://doi.org/10.1530/ETJ-24-0361](https://doi.org/10.1530/ETJ-24-0361)  \nREVIEW  \nReceived 19 November 2024 Accepted 28 January 2025 Available online 28 January 2025  \nVersion of Record published 10 February 2025  \n\n| Development of animal models to study aggressive thyroid cancers\u003Cbr>Shovan Dutta􀀁1, 2 and Jeffrey A Knauf􀀁1,2,3\u003Cbr>1Center for Immunotherapy and Precision Immuno-Oncology, Cleveland Clinic, Cleveland, Ohio, USA\u003Cbr>2Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA\u003Cbr>3Department of Otolaryngology-Head & Neck Surgery, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, Ohio, USA\u003Cbr>Correspondence should be addressed to J A Knauf: [knaufj@ccf.org](knaufj@ccf.org) |\n| --- |\n| Abstract\u003Cbr>The development of mouse models for thyroid cancer has signiﬁcantly advanced over the years, enhancing our understanding of thyroid tumorigenesis, molecular pathways and treatment responses. The earliest mouse models of thyroid cancer relied on hormone, radiation or chemical carcinogenesisto induce tumors. However, as our understanding of the genetic alterations driving thyroid cancer has expanded, more sophisticated genetic engineering techniques have been employed to create models with thyroid-speciﬁc expression of these driver mutations. While driver mutations can initiate tumorigenesis, they are often insufﬁcient to sustain cancer progression and invasion, which signiﬁcantly limits their usefulness in studying advanced thyroid cancers. Recent studies exploring the genomic landscape of advanced thyroid cancer have identiﬁed several cooperating mutations, which are secondary genetic alterations that work alongside driver mutations to promote thyroid tumor progression. Indeed, mice with a combination of oncogenic drivers and common cooperating alterations have been developed, demonstrating that these alterations function in conjunction with the oncogenic driver to promote the progression to advanced thyroid cancer. These models provide important preclinical tools to explore how cooperating alterations inﬂuence the response to therapies, particularly those targeting the oncogenic driver. This review will focus on recent publications that broaden the scope of advanced thyroid cancer models by combining thyroid-speciﬁc oncogenic driver expression with various cooperating mutations.\u003Cbr>Keywords: thyroid cancer; BRAF; RAS; mouse models; anaplastic thyroid cancer |\n\nIntroduction  \nOver the past three decades, there has been a marked improvement in animal models of thyroid cancer. The earliest mouse models relied on hormone, radiation or chemical carcinogenesis to induce thyroid tumors. These models lacked speciﬁcity for human thyroid cancer mutations and primarily focused on understanding tumor initiation and progression (1) . Their limitations included high variability, long latency, poor penetrance and in most cases, limited relevance to the genetic basis of human thyroid cancer. However, they laid the groundwork for the study of thyroid tumorigenesis. Following this, simple  \ntransgenic models were developed using promoters of thyroid-speciﬁc genes (e.g. thyroglobulin) to overexpress oncogenes identiﬁed in early genetic screens (e.g. HRASG12V, RET gene rearrangements, and BRAFV600E), speciﬁcally in mouse thyroid follicular cells. These models provided valuable insight into roles of these oncogenes in thyroid tumorigenesis. However, the oncogenes were typically overexpressed and not under the control of their endogenous promoters. In addition, many of the oncogenes induced thyroid dedifferentiation, which in turn decreased their expression. These early models (Table 1) have been  \nPublished by Bioscientiﬁca Ltd.  \n[https://etj.bioscienti](https://etj.bioscienti)ﬁ[ca.com](ca.com)  \n© 2025 the author(s)  \nThis work is licensed under a Creative Commons Attribution 4 .0 International License.  \nS Dutta & J A Knauf European Thyroid Journa","cbCaic0EgLSdFCz2","https://ap.wps.com/l/cbCaic0EgLSdFCz2","pdf",987364,15,"English","# Abstract\n# Introduction\n## Limitations of early models\n## Development of transgenic, driver-based models\n# Mouse models and driver-guided approaches","[{\"question\":\"How did early mouse models of thyroid cancer induce tumors, and what were their limitations?\",\"answer\":\"Early models used hormones, radiation, or chemical carcinogens to induce thyroid tumors. They showed high variability, long latency, poor penetrance, and limited relevance to the genetic basis of human thyroid cancer.\"},{\"question\":\"Why are driver mutations alone often insufficient for advanced thyroid cancer research?\",\"answer\":\"Although driver mutations can initiate tumorigenesis, they are frequently insufficient to sustain progression and invasion, limiting their ability to model advanced thyroid cancers.\"},{\"question\":\"What is the purpose of combining oncogenic drivers with cooperating mutations in mouse models?\",\"answer\":\"Combining drivers with cooperating alterations creates models that more accurately promote progression to advanced thyroid cancer and helps evaluate how these cooperating changes influence responses to therapies targeting oncogenic drivers.\"}]","Development of animal models to study aggressive thyroid cancers | PDF",1790157638,38,[148,152,156,160],{"page_no":22,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/447d80ff40929d2530ef8accd760eb91.webp",983,1269,{"page_no":26,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9517ab13adefeaca724170ba697bf646.webp",982,1268,{"page_no":30,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c0402d332d9ec7ae2ce644086abbc66c.webp",981,1266,{"page_no":33,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ea24c219921936eb26cfe4c5ccd70741.webp",980,1265]